Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin in Ovarian Cancer
NCT00191646Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2002
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival at 82 months. Started Oct 2002; status: completed.
02
Drugs
gemcitabine
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00191646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191646.